Keyphrases
Chain Level
100%
Neurofilament Light (NF-L)
100%
Immune Effector Cell-associated Neurotoxicity Syndrome (ICANS)
100%
Neuroaxonal Injury
25%
Nononcologic
25%
Oncologic
16%
Central Nervous System Involvement
16%
Neurologic
16%
Lymphodepletion
16%
Plasma Neurofilament Light Chain
16%
Risk Factors
8%
Non-associated
8%
Cell Infusion
8%
Medical History
8%
Central Nervous System
8%
Cytarabine
8%
Dementia
8%
Cell Therapy
8%
Clinical High Risk
8%
Chimeric Antigen Receptor T Cells (CAR-T)
8%
Radiotherapy
8%
Early Identification
8%
Tumor Burden
8%
Drug Administration
8%
Neurological Diseases
8%
Prediction Accuracy
8%
Exclusion Criteria
8%
Treatment History
8%
Patient Identification
8%
Area under the Receiver Operating Characteristic Curve
8%
Methotrexate
8%
Nervous System Diseases
8%
Potential Risk Factors
8%
Neuropathy
8%
Neural Injury
8%
Demographic Factors
8%
Median Range
8%
Prophylactic Treatment
8%
Predictive Biomarker
8%
Univariate Model
8%
Preemptive Intervention
8%
Receiver Operating Characteristic
8%
Early Screening
8%
Exposure History
8%
Multivariate Modeling
8%
Cellular Products
8%
Characteristic Classification
8%
Consequences of Treatment
8%
Medicine and Dentistry
Effector Cell
100%
Immunity
100%
Neurofilament
100%
Light Chain
100%
Toxicity and Intoxication
100%
Central Nervous System
25%
Infusion
16%
Biological Marker
8%
Neoplasm
8%
Cytarabine
8%
Cross Sectional Study
8%
Neuropathy
8%
Drug Administration
8%
Neurologic Disease
8%
Methotrexate
8%
Central Nervous System Disease
8%
Cell Therapy
8%
Nervous System Injury
8%
Vincristine
8%
Chimeric Antigen Receptor T-Cell
8%
Hexachlorophene
8%
Radiation Therapy
8%
Neuroscience
Neurotoxicity
100%
Neurofilament Light Chain
100%
Central Nervous System
25%
Blood Plasma
16%
Cell Therapy
8%
Nervous System Disorder
8%
T Cell
8%
Central Nervous System Disease
8%
Vincristine
8%
Methotrexate
8%
Chimeric Antigen Receptor
8%
Cytarabine
8%
Neuropathy
8%
Radiation Therapy
8%
Pharmacology, Toxicology and Pharmaceutical Science
Toxicity and Intoxication
100%
Neoplasm
8%
Biological Marker
8%
Cytarabine
8%
Cross-Sectional Study
8%
Drug Administration
8%
Neurologic Disease
8%
Methotrexate
8%
Neuropathy
8%
Vincristine
8%
Nervous System Injury
8%
Chimeric Antigen Receptor
8%
Central Nervous System Disease
8%
Hexachlorophene
8%